Linical's Growth Strategy

Linical's Growth Strategy

Global development of new drugs originating in
Japan is increasing

Linical has offices in Japan and other parts of Asia, the United States, and Europe to support global development strategies for pharmaceutical companies. Our locations in each country are staffed with personnel who are thoroughly familiar with the drug development situation, and we have established an environment enabling communication based on Japanese language.
In particular, in global clinical trials for difficult areas such as oncology and the central nervous system, early development stages are conducted in Japan with Linical serving as a contact point, and then development is expanded to offices in Japan and other parts of Asia. Late stages of development are conducted in Japan/Asia, the United States and Europe with the aim of simultaneous release of new drugs.

Establishment of a Global Organization is Progressing
(As of June 22, 2016)

Japan
  • 300-person CRO business
  • Steady acquisition of profit through expansion of CMA business
Asia
  • Consideration of expansion into Hong Kong, China and the Philippines by LINICAL TAIWAN CO., LTD.
Europe
  • Aiming for increased profitability by being more competitive
  • Establishment of the subsidiaries in the United Kingdom and Poland by LINICAL Europe Holding GmbH
USA
  • Relocation of head office to New York, consideration of additional offices, and strengthening of business management organization